Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ) is now available.
Beijing Chunlizhengda Medical Instruments Co., Ltd. expects a sharp jump in profitability for 2025, forecasting net profit attributable to shareholders of RMB244.99 million to RMB287.99 million, up about 96% to 130% year on year, and net profit excluding non-recurring items of RMB229.54 million to RMB269.54 million, up roughly 143% to 185%. The company attributes the projected surge in earnings to the growth potential released after its product lines were included in centralized procurement, steady progress in its international expansion, and improvements in operational management and resource allocation, which have supported sustained revenue growth and higher overall profitability, although the figures remain preliminary and unaudited.
The most recent analyst rating on (HK:1858) stock is a Buy with a HK$18.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.
More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
Beijing Chunlizhengda Medical Instruments Co., Ltd. is a PRC-incorporated medical device manufacturer listed in Hong Kong, focusing on orthopedic and related medical instruments. The group operates both domestically and internationally, with product lines that participate in China’s centralized procurement system and an expanding overseas business footprint as part of its internationalization strategy.
Average Trading Volume: 1,530,855
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.76B
Learn more about 1858 stock on TipRanks’ Stock Analysis page.